Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of products based on the extracellular matrix for the drug delivery, oncology, and dermatology markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. Its Enhanze Technology is a novel drug delivery platform, which is designed to increase the absorption and dispersion of proprietary small and large molecules.